Get the Stockscreener App
0.00
100.00%
-0.0973
After Hours:
.10
0.10
+
Zomedica Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
See More
Previous Close:
$0.0973
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$95.35M
Revenue:
$25.19M
Net Income/Loss:
$-34.53M
P/E Ratio:
0.00
EPS:
-0.036
Net Cash Flow:
$-20.62M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.1952
Zomedica Corp Stock (ZOM) Company Profile
Name
Zomedica Corp
Sector
Phone
734-369-2555
Address
100 Phoenix Drive, Suite 190, Ann Arbor, MI
Compare ZOM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZOM
Zomedica Corp
|
0.00 | 95.35M | 25.19M | -34.53M | -20.62M | -0.036 |
|
ZTS
Zoetis Inc
|
150.91 | 65.46B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 46.11B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.84B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.29 | 16.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.46 | 12.81B | 2.76B | 1.11B | 898.10M | 22.77 |
Zomedica Corp Stock (ZOM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Initiated | Dawson James | Buy |
Zomedica Corp Stock (ZOM) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System - ACCESS Newswire
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split - ACCESS Newswire
Zomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025 - Yahoo Finance
20 Stocks Insiders Were Buying In Q1 2025 - Insider Monkey
Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
Zscaler, Rocket Lab, American Tower, Intuit, and Zomedica: Insider Moves Unveiled! - TipRanks
Zomedica director Rodney Williams acquires $6,900 in stock By Investing.com - Investing.com Canada
Zomedica director Rodney Williams acquires $6,900 in stock - Investing.com
Zomedica’s CFO Jordan Scott acquires $18,600 in common stock By Investing.com - Investing.com Canada
Zomedica director Christopher MacLeod buys $8,437 in stock - Investing.com India
Zomedica’s CFO Jordan Scott acquires $18,600 in common stock - Investing.com
Zomedica director Christopher MacLeod buys $8,437 in stock By Investing.com - Investing.com Australia
Zomedica CEO Larry Heaton acquires $29,702 in common stock By Investing.com - Investing.com Canada
Zomedica senior vice president buys $48,998 in common stock By Investing.com - Investing.com India
Zomedica director Johnny Powers acquires $33,650 in common stock By Investing.com - Investing.com Australia
Zomedica director Williams acquires $6,900 in common stock By Investing.com - Investing.com Canada
Zomedica director Christopher MacLeod acquires $8,437 in stock - Investing.com India
Zomedica COO Blair Anthony K acquires $30,000 in common stock By Investing.com - Investing.com Australia
Zomedica director Christopher MacLeod acquires $8,437 in stock By Investing.com - Investing.com South Africa
Zomedica director Jeffrey Rowe buys $96,098 in stock By Investing.com - Investing.com South Africa
Zomedica director Johnny Powers acquires $33,650 in common stock - Investing.com
Zomedica COO Blair Anthony K acquires $30,000 in common stock - Investing.com
Zomedica CEO Larry Heaton acquires $29,702 in common stock - Investing.com
Zomedica director Jeffrey Rowe buys $96,098 in stock - Investing.com
Zomedica senior vice president buys $48,998 in common stock - Investing.com
Zomedica director Williams acquires $6,900 in common stock - Investing.com
Zomedica Reports Record Revenue and Strong Growth - TipRanks
Earnings call transcript: Zomedica Q4 2024 shows revenue growth - Investing.com India
Zomedica Reports Record Revenue of $7.9 Million for the Fourth Quarter and $27.3 Million for the Full Year 2024; 70% Gross Margin, and $71 Million in Liquidity to Support Growth - ACCESS Newswire
Zomedica (ZOM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Zomedica Transitions to OTCQB Market Following NYSE Delisting - TipRanks
Zomedica Corp. Announces Transition to OTCQB Venture Market - Herald Palladium
About Us - Financial Content
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone - ACCESS Newswire
Zomedica Interview To Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
Zomedica Corp Stock (ZOM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):